BBIO250516P15000
- 0.00
- 0.000.00%
BridgeBio Pharma Newsroom
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and BridgeBio Pharma (BBIO)
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $60
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $70
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $55
UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $72
BridgeBio Pharma Is Maintained at Overweight by Piper Sandler
BridgeBio Pharma Analyst Ratings
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $50 to $67
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and BridgeBio Pharma (BBIO)
Wells Fargo Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $53
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Raymond James Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $57